导师介绍
王杰 副研究员
王杰 博士
基础医学院病原生物学系，副研究员，博士生导师
联系方式：办公地址：医学科技楼北楼B602-2室
Email: wangjie2015@bjmu.edu.cn
研究方向：病毒感染相关疾病诊疗及发病机制研究
主要从事乙型肝炎病毒（HBV）感染的分子诊断和靶向治疗，HBV与宿主因子相互作用，以及病毒感染相关肿瘤发生机制方面的研究
主要学术任职：
中国研究型医院学会病毒肿瘤学专业委员会委员，中华预防医学会促进消除病毒性肝炎工作委员会委员，中华医学会医学病毒学分会青年委员会委员及临床病毒学组委员，中华医学会肝病学分会青年委员会委员及肝炎学组、肝癌学组和肝病基础医学与实验诊断协作组委员。
主要承担课题：
1. 国家自然科学基金面上项目，2022.01-2025.12，负责人
2. 国家自然科学基金面上项目，2020.01-2023.12，负责人
3. JW后勤部JM融合重点项目，2019.01-2022.12，子课题负责人
4. 北京市自然科学基金面上项目，2018.01-2020.12，负责人
5. 国家“传染病防治”科技重大专项，2017.01-2020.12，任务负责人（两项）
6. 国家自然科学基金面上项目，2017.01-2020.12，负责人
代表性论文：（#第一作者，*通讯作者）
1. Huang H#, Han Q#, Zheng H, Liu M, Shi S, Zhang T, Yang X, Li Z, Xu Q, Guo H*, Lu F, Wang J*. MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. Cell Death & Disease. 2022; 13(1):13.
2. Yu G, Chen R, Zheng S, Liu Y, Zou J, Gu Z, Jiang B, Gao Q, Dai L*, Peng J*, Wang J*, Lu F*. A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. Emerging Microbes & Infections. 2022; 11(1):775-785.
3. Li Y, Xiao Y, Li L, Song Y, Zhai X, Liu J, Duan Z, Yan L, Ding F, Liu J, Zhu L, Jiang J, Zou H, Li L, Liang C, Wang J*, Li J*. The dynamic changes of HBV quasispecies diversity in infancy after immunoprophylaxis failure: a prospective cohort study. Virology Journal. 2021; 18:236.
4. Lu Y#, Song Y#, Zhai X, Zhu F, Liu J, Chang Z, Li Y, Xiao Y, Li L, Liu M, Liu J, Duan Z, Zou H, Zhuang H, Wang J*, Li J*. Maternal Hepatitis B e Antigen can be an Indicator for Antiviral Prophylaxis of Perinatal Transmission of Hepatitis B Virus. Emerging Microbes & Infections. 2021; 10(1):555-564.
5. Xiao Y, Sun K, Duan Z, Liu Z, Li Y, Yan L, Song Y, Zou H, Liu J, Zhuang H*, Wang J*, Li J*. Quasispecies characteristic in “a” determinant region is a potential predictor for the risk of immunoprophylaxis failure of mother-to-child-transmission of sub-genotype C2 hepatitis B virus: a prospective nested case-control study. Gut. 2020; 69(5):933-941.
6. Li Y#, Liu Z#, Song Y, Xiao Y, Jiang J, Li L, Zhai X, Liu J, Duan Z, Ding F, Liu J, Zhuang H, Zhu L, Jiang J, Zou H, Wang J*, Li J*. Reduction of the occurrence of occult HBV infection in infants by increasing the dose of hepatitis B vaccine: A large prospective cohort study. Emerging Microbes & Infections. 2020; 9(1):1881-1891.
7. Shi S, Liu M, Xi J, Liu H, Guan G, Shen C, Guo Z, Zhang T, Xu Q, Kudereti D, Chen X, Wang J*, Lu F*. Sex-determining region Y box 4 (SOX4) suppresses hepatitis B virus replication by inhibiting hepatocyte nuclear factor 4α expression. Antiviral Research. 2020; 176: 104745.
8. Chen R, Huang H, Liu H, Xi J, Ning J, Zeng W, Shen C, Zhang T, Yu G, Xu Q, Chen X, Wang J*, Lu F*. Friend or Foe? Evidences Indicate Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein. Small. 2019; 15(38): e1902686.
9. Wang J, Jia J, Chen R, Ding S, Xu Q, Zhang T, Chen X, Liu S*, Lu F*. RFX1 participates in doxorubicin-induced hepatitis B virus reactivation. Cancer Medicine. 2018; 7(5):2021-2033.
10. Wang J#, Chen X#, Wu Y#, Cao Z, Wang L, Huang H, Chen X*, Lu F*. Serum HBV RNA is a potential predictor of hepatitis B surface antigen reversion. Hepatology Communications. 2018; 2(10):1168-1171.
11. Wang J, Sheng Q, Ding Y, Chen R, Sun X, Chen X, Dou X*, Lu F*. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. Journal of Hepatology. 2018; 68:847-849.
12. Huang H#, Wang J#, Li W, Chen R, Chen X, Zhang F*, Xu D*, Lu F*. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals. Journal of Clinical Virology. 2018; 99-100:71-78.
13. Wang J#, Du M#, Huang H, Chen R, Niu J, Jiang J*, Zhuang H, Lu F*. Consistent loss of serum HBV RNA might predict the "para-functional cure" of chronic hepatitis B. Journal of Hepatology. 2017; 66(2):462-463.
14. Wang J#, Chen R#, Zhang R#, Ding S, Zhang T, Yuan Q, Guan G, Chen X, Zhang T, Zhuang H, Nunes F, Block T, Liu S, Duan Z, Xia N*, Xu Z*, Lu F*. The gRNA-miRNA-gRNA ternary cassette combining CRISPR/Cas9 with RNAi approach strongly inhibits hepatitis B virus replication. Theranostics. 2017; 7(12):3090-3105.
15. Wang J#, Shen T#, Huang X#, Kumar GR#, Chen X, Zeng Z, Zhang R, Chen R, Li T, Zhang T, Yuan Q, Li PC, Huang Q, Colonno R, Jia J, Hou J, McCrae MA, Gao Z*, Ren H*, Xia N*, Zhuang H, Lu F*. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. Journal of Hepatology. 2016; 65(4):700-710.
16. Wang J, Ding S, Duan Z, Xie Q, Zhang T, Zhang X, Wang Y, Chen X*, Zhuang H, Lu F*. The role of p14ARF-HDM2-p53 in SOX6-mediated tumor suppression. Oncogene. 2016; 35(13):1692-1702.
17. Wang J, Xu ZW, Liu S, Zhang R, Ding S, Xie X, Chen X, Zhuang H, Lu F*. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World Journal of Gastroenterology. 2015; 21(32): 9554-9565.
18. Wang J, Liu B, Wang N, Lee YM, Liu C, Li K*. TRIM 56 is a virus- and interferon-inducible E3 ubiquitin ligase that restricts pestivirus infection. Journal of Virology. 2011; 85(8):3733-3745.